Insights

Gathering insights about SER…

Similar companies to SER

SER Tech Stack

SER uses 8 technology products and services including Open Graph, RSS, Font Awesome, and more. Explore SER's tech stack below.

Open Graph
Content Management System
RSS
Content Management System
Font Awesome
Font Scripts
TweenMax
Javascript Frameworks
Underscore.js
Javascript Libraries
Priority Hints
Performance
reCAPTCHA
Security
prettyPhoto
Web Tools And Plugins

Media & News

SER Group Doubles Down on SAP Document Automation Expertise With Acquisition of AFI Solutions
BONN, Germany--(BUSINESS WIRE)--SER Group, a leading provider of Intelligent Content Automation solutions with its highly rated Doxis platform, today announced the acquisition of AFI Solutions, a specialist in the digitalization and optimization of document-centric processes in SAP. Driven by crucial and urgent initiatives to increase productivity and reduce costs through the automation of document-based processes, along with the need to support sweeping new e-invoice laws and the upcoming enfo.
Mar 25, 2025 | www.businesswire.com
Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
HUNTSVILLE, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the full year ended December 31, 2024 and provided recent business highlights.
Mar 24, 2025 | www.globenewswire.com
Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting
HUNTSVILLE, AL, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, announced that Randall Moreadith, M.D., Ph.D., Chief Development Officer, will present new data at the ACS Spring 2025 Meeting and Expo in San Diego, CA. His presentation, titled "A Non-Immunogenic LNP for Gene Delivery: Characterization of Poly(oxazoline) Lipid Nanoparticles," will highlight findings on the immunogenic profile of Serina's proprietary POZ-lipid technology.
Mar 24, 2025 | www.globenewswire.com
Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach
FDA has provided input on key elements of the SER-155 allo-HSCT clinical development plans including support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) as of 30 days post HSCT in the next study
Mar 03, 2025 | www.globenewswire.com
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors
HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Jay Venkatesan, MD, MBA, to its Board of Directors. Dr. Venkatesan brings deep expertise in biotechnology investment, company building, and strategic growth, having successfully led and advised multiple biopharma companies through pivotal stages of development, including high-profile mergers and acquisitions.
Feb 12, 2025 | www.globenewswire.com
Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients
HUNTSVILLE, Feb. 03, 2025 (GLOBE NEWSWIRE) -- S erina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced the successful closing of the second $5 million tranche of its previously announced $10 million equity financing with strategic shareholder JuvVentures (UK) Limited. The transaction provides Serina with funding to continue advancing SER-252 (POZ-apomorphine), enabled by its proprietary POZ Platform™ drug optimization technology, into a Phase 1 clinical trial in advanced Parkinson's disease patients in the second half of 2025. The closing represented the second tranche of the $10 million total financing announced on December 2, 2024.
Feb 03, 2025 | www.globenewswire.com
Serina Therapeutics Announces Sale of UniverXome Subsidiary
- Transaction eliminates $11.2 million in debt, strengthening financial position - HUNTSVILLE, AL, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced the sale of its UniverXome subsidiary. The transaction was finalized on December 23, 2024 and eliminated $11.2 million in associated subsidiary-level debt, positioning Serina with a debt-free balance sheet heading into 2025.
Jan 15, 2025 | www.globenewswire.com

SER's Email Address Formats

SER uses at least 1 format(s):

SER Email Formats	Example	Percentage
First@serassociates.com	John@serassociates.com	63%
Last@serassociates.com	Doe@serassociates.com	29%
LastFi@serassociates.com	DoeJo@serassociates.com	4%
FirstL@serassociates.com	JohnD@serassociates.com	4%

Frequently Asked Questions

What is SER's phone number?

You can contact SER's main corporate office by phone at

+1-215-643-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is SER's stock symbol?

SER is a publicly traded company; the company's stock symbol is SER.

What is SER's official website and social media links?

SER's official website is serassociates.com and has social profiles on LinkedIn.

What is SER's SIC code NAICS code?

SER's SIC code is 8742 - Management Consulting Services NAICS code is 5613 - Employment Services.

How many employees does SER have currently?

As of December 2024, SER has approximately 239 employees across 6 continents, including AsiaEuropeSouth America. Key team members include Chief Financial Officer: G. M.Chief Technology Officer At Ser, Ukraine: G. B.Vice President Talent: R. R.. Explore SER's employee directory with LeadIQ.

What industry does SER belong to?

SER operates in the Staffing and Recruiting industry.

What technology does SER use?

SER's tech stack includes Open GraphRSSFont AwesomeTweenMaxUnderscore.jsPriority HintsreCAPTCHAprettyPhoto.

What is SER's email format?

SER's email format typically follows the pattern of . Find more SER email formats with LeadIQ.

When was SER founded?

SER was founded in 2000.

SER

Staffing and Recruiting201-500 Employees

SER is a “retained” executive search firm focused exclusively on building world class sales and marketing organizations. We have served over 200 clients since inception and work exclusively with the top 10% of talent on the market. All candidates are "internally validated" prior to submission. Our goal is to create long-term strategic partnerships with our clients.

"Driving Growth & Success Through Technology & Talent"

www.serassociates.com

Company Overview

Phone number: +1-215-643-****
Website: serassociates.com
SIC Code: 8742 - Management Consulting Services
Stock Symbol: SER
NAICS Code: 5613 - Employment Services
Founded: 2000
Employees: 201-500

Media & News

Funding & Financials

$10M
SER's revenue is in the range of $10M

Funding & Financials

$10M
SER's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to SER

HSF

HITEC

SHPE

ELC

SER Tech Stack

Media & News

SER Group Doubles Down on SAP Document Automation Expertise With Acquisition of AFI Solutions

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Serina Therapeutics Announces Sale of UniverXome Subsidiary

SER's Email Address Formats

Frequently Asked Questions

What is SER's phone number?

What is SER's stock symbol?

What is SER's official website and social media links?

What is SER's SIC code NAICS code?

How many employees does SER have currently?

What industry does SER belong to?

What technology does SER use?

What is SER's email format?

When was SER founded?

SER

Company Overview

Media & News

SER Group Doubles Down on SAP Document Automation Expertise With Acquisition of AFI Solutions

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?